Trials / Completed
CompletedNCT02590887
Safety and Efficacy of a Drink Containing Lupine Protein Hydrolysates on the Immune, Oxidative and Metabolic Status
Clinical Study to Assess the Immunomodulatory and Antioxidant Effects of a Beverage Manufactured From Lupine Protein Hydrolysates in Healthy Volunteers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- University of Seville · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the health effects of the 4 weeks daily intake of a drink manufactured from lupine protein hydrolysates in healthy volunteers. For that, blood markers of inflammation, oxidative stress, carbohydrate, lipid, protein and liver metabolism, together with general hematology and blood coagulation will be assessed at baseline time (day 0) and after drink ingestion (day +14 and +28).
Detailed description
The main objective of the present study is to verify the hypothesis that the intake of the drink based on lupine peptides is safe and has beneficial effects on the immune and oxidative status. The secondary objectives are: * Assess the effect of the drink on biological parameters of the carbohydrate, lipid, renal and hepatic metabolism as well as hematology analysis. * Assess whether the new product is well tolerated. * Evaluate the effect of the drink on the general health of the volunteers through the Short Form-36 health survey. * Determine the degree of drink acceptability through the acceptability Likert test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Drink manufactured from lupine peptides | Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (14, and 28 days) drinking the beverage. |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2015-10-29
- Last updated
- 2020-10-23
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02590887. Inclusion in this directory is not an endorsement.